@article{d824be23e1b8459292b27609a0c0d75c,
title = "Immunosuppressant-associated eruptions in pediatric inflammatory bowel disease: A case-control study",
abstract = "Paradoxically, immunosuppressive therapy for inflammatory bowel disease (IBD) can induce psoriasiform or eczematous eruptions. This case-control study identified infliximab exposure, Crohn's disease, and history of inflammatory skin conditions as significant risk factors for these eruptions in children with IBD. Our results also showed possible trends in age and race.",
keywords = "Crohn's disease, adalimumab, eczema, immunosuppression, inflammatory bowel disease, infliximab, psoriasis",
author = "Bruin Pollard and Utterson, {Elizabeth C.} and Samson, {Charles M.} and Coughlin, {Carrie C.}",
note = "Funding Information: This study was supported by award TL1TR002344 from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the views of the NIH. Publisher Copyright: {\textcopyright} 2022 Wiley Periodicals LLC.",
year = "2022",
month = jul,
day = "1",
doi = "10.1111/pde.14985",
language = "English",
volume = "39",
pages = "563--566",
journal = "Pediatric Dermatology",
issn = "0736-8046",
number = "4",
}